CEBP CTRC-AACR San Antonio Breast Cancer Symposium 09 AM Call for Abstracts w/deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Djuric, Z.
Right arrow Articles by Kosir, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Djuric, Z.
Right arrow Articles by Kosir, M. A.
Cancer Epidemiology Biomarkers & Prevention Vol. 10, 147-149, February 2001
© 2001 American Association for Cancer Research


Short Communications

Levels of 5-Hydroxymethyl-2'-deoxyuridine in DNA from Blood of Women Scheduled for Breast Biopsy1

Zora Djuric2, Lance K. Heilbrun, Samir Lababidi, Egle Berzinkas, Michael S. Simon and Mary A. Kosir

Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201

Systemic oxidative stress is thought to contribute to risk of various cancers, including breast cancer. DNA repair ability also has been associated with breast cancer risk. In this work, we examined levels of oxidative DNA damage as an indication of breast cancer risk in women because oxidative DNA damage levels should reflect the net balance of oxidative stress and DNA repair ability. Levels of 5-hydroxymethyl-2'-deoxyuridine, one form of oxidative DNA damage, were measured in DNA from blood of women scheduled for breast biopsy. The blood samples analyzed included women whose biopsy results indicated invasive breast cancer, high-risk lesions (atypical hyperplasia or carcinoma in situ), or benign lesions. Mean levels of 5-hydroxymethyl-2'-deoxyuridine were significantly higher in blood of women who had high risk or invasive breast lesions versus women with benign lesions. If atypical hyperplasia or carcinoma in situ are precursor lesions for breast cancer, then these results suggest that oxidative DNA damage may be involved in the cancer process before invasive cancer develops.




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
S. H. Taplin, L. Ichikawa, M. U. Yood, M. M. Manos, A. M. Geiger, S. Weinmann, J. Gilbert, J. Mouchawar, W. A. Leyden, R. Altaras, et al.
Reason for Late-Stage Breast Cancer: Absence of Screening or Detection, or Breakdown in Follow-up?
J Natl Cancer Inst, October 20, 2004; 96(20): 1518 - 1527.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. Wallstrom, K. Frenkel, E. Wirfalt, B. Gullberg, J. Karkoszka, J. Seidegard, L. Janzon, and G. Berglund
Antibodies against 5-Hydroxymethyl-2'-deoxyuridine Are Associated with Lifestyle Factors and GSTM1 Genotype: A Report from the Malmo Diet and Cancer Cohort
Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 444 - 451.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. R. Smith, M. S. Miller, K. K. Lohman, L.D. Case, and J. J. Hu
DNA damage and breast cancer risk
Carcinogenesis, May 1, 2003; 24(5): 883 - 889.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.